PNC-27 10 MG
PNC-27 10 MG
PNC-27 is a 32-amino-acid investigational peptide designed from a portion of the p53 tumor suppressor protein linked to a cell-penetrating sequence. It is being studied as a potential targeted anti-cancer peptide, but it is not FDA-approved, not an established cancer treatment, and has not demonstrated safety or efficacy in human clinical trials. Most evidence comes from cell culture and animal research.
What is PNC-27 studied for?
Researchers have investigated PNC-27 primarily for:
- Selective targeting of cancer cells
- Breast cancer
- Leukemia
- Melanoma
- Colon cancer
- Pancreatic cancer
- Prostate cancer
- Other tumor types that express HDM2 (also called MDM2) on their cell membranes.
Proposed mechanism of action
Unlike many cancer therapies that attempt to trigger apoptosis (programmed cell death), PNC-27 appears to work differently in preclinical models:
- It binds to HDM2 proteins found on the membranes of certain cancer cells.
- It forms pores in the cancer cell membrane.
- The damaged membrane causes rapid cell lysis (necrosis).
- Normal cells appear to be much less susceptible because they generally lack membrane-associated HDM2.
Common research stacks
In laboratory research, investigators have explored PNC-27:
- By itself (most common)
- With traditional chemotherapy agents to evaluate possible additive or synergistic effects
- Alongside studies of the p53/MDM2 pathway
- Compared with its closely related analog PNC-28
It's worth noting that many combinations discussed online with peptides such as BPC-157, TB-500, or growth hormone are speculative and are not supported by peer-reviewed evidence for cancer treatment.
Advantages researchers are interested in
Potential advantages suggested by early research include:
- Selective activity against certain cancer cells
- Novel mechanism compared with chemotherapy
- May work independently of some p53 mutations
- Rapid destruction of susceptible cancer cells in laboratory models